Evidence map›Paper›PMID 26239222›Full record

ArticleJournal of neurology2015

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.

Hans-Peter Hartung, Ludwig Kappos, Douglas S Goodin, Paul O'Connor, Massimo Filippi, Barry Arnason, Giancarlo Comi, Stuart Cook, Douglas Jeffery, John Petkau and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hans-Peter HartungDepartment of Neurology, Heinrich Heine University, Düsseldorf, Germany. Hans-Peter.Hartung@uni-duesseldorf.de.
Ludwig KapposNeurology, University of Basel and University Hospital, Basel, Switzerland.
Douglas S GoodinDepartment of Neurology, University of California, San Francisco, CA, USA.
Paul O'ConnorDivision of Neurology, St. Michael's Hospital, University of Toronto, Toronto, Canada.
Massimo FilippiNeuroimaging Research Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Barry ArnasonDepartment of Neurology, University of Chicago Surgery Brain Research Institutes, Chicago, IL, USA.
Giancarlo ComiDepartment of Neurology and Institute of Experimental Neurology, Università Vita-Salute San Raffaele, Milan, Italy.
Stuart CookDepartment of Neurology and Neurosciences, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Douglas JefferyWake Forest University School of Medicine, Winston-Salem, NC, USA.
John PetkauDepartment of Statistics, University of British Columbia, Vancouver, Canada.
Richard WhiteDepartment of Statistics, University of British Columbia, Vancouver, Canada.
Timon BogumilBayer Pharma AG, Berlin, Germany.
Karola BeckmannBayer Pharma AG, Berlin, Germany.
Brigitte StemperBayer Pharma AG, Berlin, Germany.
Gustavo SuarezBayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
Rupert SandbrinkDepartment of Neurology, Heinrich Heine University, Düsseldorf, Germany.
Christoph PohlBayer Pharma AG, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disease of the CNS that requires long-term treatment. The identification of patient characteristics that can help predict disease outcomes could improve care for patients with MS. The objective of this study is to identify predictors of disease activity in patients from the BEYOND trial. This regression analysis of patients with relapsing-remitting MS from BEYOND examined the predictive value of patient characteristics at baseline and after 1 year of treatment with interferon beta-1b 250 μg every other day for clinical and MRI outcomes after year 1 of the study. 857 and 765 patients were included in the analyses of clinical and MRI outcomes, respectively. In multivariate analyses of age, a higher number of relapses in the past 2 years, ≥3 new MRI lesions in the first year, and, especially, a higher number of relapses in year 1 predicted the future occurrence of relapses. By contrast, age, MRI activity, and the presence of neutralizing antibodies in the first year were principally predictive of future MRI activity. In patients with continued clinical disease activity or substantial MRI activity on therapy, an alternative therapeutic approach should be strongly considered.

Indexed as

Outcome Assessment, Health CareAdjuvants, ImmunologicAdultAge FactorsFemaleFollow-Up StudiesHumansInterferon beta-1bMagnetic Resonance ImagingMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingPrognosisRecurrenceAdjuvants, ImmunologicInterferon beta-1bInterferon beta-1bMRI lesionMultiple sclerosisPredictorRelapse

Identifiers

PMID26239222
PMCPMC4639578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.